Medco turned an oil-crash loss into record profit via cost cuts and a Corridor bet

Indonesia's Medco Energi entered 2015 as a mid-sized oil and gas producer facing the worst price crash in a generation. Revenue collapsed and the company posted a US$188 million net loss for the year. Rather than wait for prices to recover, management attacked what it controlled: production rose from 56 to 66 MBOEPD in 2016 while cash operating costs per barrel fell from US$12.3 to US$8.8.

The cost discipline flipped the P&L: 2016 net profit came in at US$185 million. Medco used that foundation to place a counter-cyclical bet — it agreed to buy ConocoPhillips' 54% interest in the Corridor Block production sharing contract and a 35% stake in the Transasia Pipeline for US$1.355 billion, effective January 1, 2021 and completed in March 2022.

The acquisition roughly tripled Medco's production base and delivered record results when prices recovered: audited 2022 results showed net income of US$531 million — more than ten times the prior year — EBITDA of US$1.593 billion, operating cash flow of US$1.116 billion, and production up 73% to 163 MBOEPD. Medco also repaid US$415 million of the US$850 million acquisition debt within the first year.

2016 swung to US$185M profit (production 56→66 MBOEPD, cash cost US$12.3→US$8.8); after the US$1.355B Corridor buy, 2022 net income hit a record US$531M.

Medco cut unit cash costs from US$12.3 to US$8.8 per BOE while growing production, so the 2016 recovery did not depend on oil prices.

The Corridor purchase added 51 MBOEPD of production at a depressed asset price, timed when competitors were selling.

Management funded and then rapidly deleveraged the deal, paying down US$415M of acquisition debt in 2022.

Diversification into power (Riau IPP, Sumbawa solar) added non-oil cash flows that steadied the business.

Cut unit costs first, then buy quality assets counter-cyclically: Medco's US$185M 2016 profit funded the Corridor deal, and 2022 net income hit US$531M, ten times the year before.

By end-2022 net debt-to-EBITDA was 1.4x, Medco's best ever, with US$737 million cash and US$456 million of bonds retired early. It started 2023 with new projects — Ijen geothermal, Sumbawa regasification and more Natuna gas — while Corridor gas kept flowing to Singapore under new sales agreements. The crash-era discipline carried straight into the boom.